GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Net Income

Bottom-line profit after all expenses, interest, and taxes.

GSK plcNYSE: GSK

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income dips below year-ago levels

Q2 FY2026 net income of £435M fell 69.9% year over year, behind the +40.8% change in trailing-twelve-month net income. Sequentially, it fell 75.0% from the prior quarter. Over 3 fiscal years it compounded at -27.4% a year.

Context

  • Net income amounted to 17.5% of revenue in FY2025, up 9.3 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 16 analysts of £7.5B (+31.2%) for the fiscal year ending Dec 2026, a slowdown from the +122.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
£435M-75.0% QoQ
Last fiscal yearDec 2025
£5.72B+122.0% YoY
LTMJun 2026
£4.82B+40.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-69.9%+2.2%+72.0 pp
1 year+122.0%+31.2%-90.8 pp
3-year CAGR-27.4%+13.3%+40.7 pp
5-year CAGR+9.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

GBP · from the income statement

Latest · FY2025
5.72B GBP
Year-over-year change
+122.0%
4-year CAGR
+6.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GSK compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +40.8% is the 2nd highest of 10, against a peer median of -6.6%.
  • Net income amounts to 14.5% of revenue for GSK, versus a peer median of 17.7%.
GSK Competitors
Net Income for GSK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 116.44B DKK+4.8%+22.6%35.3%
LLYEli Lilly and CompanyLTM Jun 2026$26.71B USD+93.6%+49.0%33.5%
JNJJohnson & JohnsonLTM Sep 2026$16.1B USD-35.9%+14.3%16.2%
NVSNovartis AGLTM Jun 2026$12.76B USD-6.6%+26.4%22.9%
AZNAstraZeneca PLCLTM Sep 2026$10.99B USD+16.9%+46.1%17.7%
AMGNAmgen Inc.LTM Jun 2026$8.74B USD+32.1%+5.6%22.9%
GSKGSK plcLTM Jun 2026£4.82B GBP+40.8%-27.4%14.5%
PFEPfizer Inc.LTM Jun 2026$4.33B USD-59.7%-37.2%6.8%
SNYSanofiLTM Jun 2026€3.96B EUR-56.6%-2.3%8.1%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
Peer median (excluding GSK) —-6.6%+14.3%17.7%

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue24.7B29.32B30.33B31.38B32.67B
Cost of Revenue8.16B9.55B8.57B9.05B9.02B
Gross Profit16.53B19.77B21.76B22.33B23.65B
Gross Margin66.9%67.4%71.8%71.2%72.4%
Research & Development5.02B5.49B6.22B6.4B7.53B
Selling, General & Admin7.07B8.37B9.39B11.02B9.09B
Operating Expenses12.18B13.34B15.02B18.31B15.31B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
EBITDA6.49B8.6B9.08B6.67B10.4B
EBITDA Margin26.3%29.3%29.9%21.3%31.8%
Operating Income4.36B6.43B6.75B4.02B8.34B
Operating Margin17.6%21.9%22.2%12.8%25.5%
Interest Income28M64.27M40M67.39M56M
Interest Expense784M855.53M775M657.58M687M
Other Income / Expenses(758M)(805M)(681M)(544M)(937M)
Income Before Tax3.6B5.63B6.06B3.48B7.4B
Pre-Tax Margin14.6%19.2%20.0%11.1%22.7%
Income Tax Expense83M707M756M526M1.11B
Net Income4.39B14.96B4.93B2.58B5.72B
Net Margin17.8%51.0%16.2%8.2%17.5%
EPS (Basic)2.747.442.441.262.82
EPS (Diluted)2.707.322.401.242.78
Weighted Avg Shares1.6B2.01B2.03B2.04B2.03B
Weighted Avg Shares (Diluted)1.62B2.04B2.06B2.07B2.06B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.